Going beyond gene edited CARs
From CAR-T cells to protein degradation
Do we need to pay more attention to the underlying biology in aggressive lymphomas?
Challenges and opportunities in the myeloma niche
Finding the sweetspot in early stage cancer drug development
Improving cell therapy performance with a multitude of innovative strategies
A rising area of interest in the CAR-T cell space
What will be the emerging products and regimens to watch out for in aggressive lymphomas?
An in-depth look at what's behind an upcoming milestone
How can performance of T cell therapy be improved?
The evolving BMS-Celgene pipeline and what's coming next in new developmental twists
A look at an evolving niche in hematologic malignancies
Some key subtleties and nuances to watch out for in the Menin niche
The importance of T cell exhaustion and exploring ways to avoid it
